Systemic markers of inflammation after coronary angioplasty;Marqueurs systémiques de l'inflammation après angioplastie coronaire

Presse Medicale

Volumn 30, Issue 34, 2001, Pages 1701-1705

  Donal, E ^a   Allal, J ^a   Christiaens, L ^a   Lecron, J C ^a   Ragot, S ^a   Coisne, D ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROGNOSIS; RESTENOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY RESTENOSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PROGNOSIS;

EID: 0035904637     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
2. C-Reactive protein and coronary artery disease: Additional evidence of the implication of an inflammatory process in acute coronary syndrome
3. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
4. Elevated levels of C-Reactive protein at discharge in patients with unstable angina predict recurrent instability
5. Novel inflammatory markers of coronary risk: Theory vesus practice
6. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilote study
7. Treatment with antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of ROXIS study
8. Randomized secondary prevention trial of Azithromycin in patients with coronary artery disease and serological evidence for Chlamydia Pneumoniae infection: The Azithromycin in coronary artery disease: Elimination of myocardial infection with chlamydia (ACADEMIC) study
9. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
10. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study
11. Increasing levels of interleukin(IL)-1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
12. Plasma concentration of interteukin-6 and the risk of future myocardial infarction among apparently healthy men
13. Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction
14. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina
15. Coronary angioplasty induces a systemic inflammatory response
16. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
17. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
18. Plasma level of C-reactive protein after coronary stent implantation
19. Auti-immune and inflammatory responses may have an addictive effect in post-percutaneous transluminal coronary angioplasty restenosis
20. Plaque inflammation in restenosis coronary lesions of patients with stable or unstable angina
21. Comparison of activation process of platelets and neutrophils after coronary Stent implantation versus balloon angioplasty for stable angina pectoris
22. Role of novel markers of inflammation in patients with stable coronary heart disease
23. Elevated levels of interleukin-6 in unstable angina
24. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
25. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
26. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
27. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study